Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022143 | 0.83 | PTPN1 (0.66) | PTGS1MAOBPTGS2ALOX5PTPN1 | |
| SCHEMBL31545595 | 0.80 | HPGD (0.50) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL3174144 | 0.78 | MAOA (0.53) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL2638446 | 0.78 | HTT (0.50) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL10010839 | 0.77 | SRD5A1 (0.46) | PTGS1HTTMEN1MAPTHPGD | |
| SCHEMBL24805118 | 0.76 | CYP19A1 (0.45) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL14283811 | 0.75 | CYP19A1 (0.51) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL14283808 | 0.75 | MAOB (0.50) | MAOACYP19A1MAOBPTGS2MEN1 | |
| SCHEMBL24804446 | 0.75 | HTT (0.49) | MAOAPTGS1CYP19A1MAOBPTGS2 | |
| SCHEMBL3564545 | 0.73 | CYP19A1 (0.52) | MAOAPTGS1CYP19A1MAOBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016133940-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | MCL1, HCCS, CASP3 | MAOA 2371/4885PTGS1 2173/4885CYP19A1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.